Is UCB (EBR:UCB) A Risky Investment?
Dec 24
Have your own idea? Try our Stock Screener
Belgian (BEL20) Pharma Industry Analysis
UpdatedFeb 08, 2025
DataAggregated Company Financials
Companies3
- 7D0.5%
- 3M2.8%
- 1Y97.6%
- YTD-0.3%
Over the last 7 days, the Pharma industry has dropped 2.0%, driven by UCB declining 2.0%. This takes the industry's 12 month performance to a gain of 104%. Looking forward, earnings are forecast to grow by 28% annually.
Industry Valuation and Performance
Has the Belgian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 08 Feb 2025 | €42.9b | €5.5b | €316.8m | 112.6x | 135.3x | 7.8x |
| Mon, 06 Jan 2025 | €43.1b | €5.5b | €316.8m | 112.5x | 135.9x | 7.9x |
| Wed, 04 Dec 2024 | €42.0b | €5.5b | €316.8m | 108.7x | 132.7x | 7.7x |
| Fri, 01 Nov 2024 | €40.4b | €5.5b | €316.8m | 105.7x | 127.5x | 7.4x |
| Sun, 29 Sep 2024 | €36.6b | €5.5b | €314.6m | 96.2x | 116.4x | 6.7x |
| Tue, 27 Aug 2024 | €36.1b | €5.5b | €314.6m | 92.8x | 114.7x | 6.6x |
| Thu, 25 Jul 2024 | €33.1b | €5.2b | €415.4m | 68.7x | 79.7x | 6.4x |
| Sat, 22 Jun 2024 | €31.4b | €5.2b | €415.4m | 65x | 75.6x | 6.1x |
| Mon, 20 May 2024 | €28.3b | €5.2b | €415.4m | 59x | 68.1x | 5.5x |
| Wed, 17 Apr 2024 | €27.1b | €5.2b | €415.4m | 56.4x | 65.3x | 5.2x |
| Fri, 15 Mar 2024 | €24.4b | €5.2b | €412.4m | 51.9x | 59.2x | 4.7x |
| Sun, 11 Feb 2024 | €21.7b | €5.1b | €404.7m | 47.6x | 53.6x | 4.2x |
| Tue, 09 Jan 2024 | €19.4b | €5.1b | €404.7m | 43x | 47.8x | 3.8x |
| Thu, 07 Dec 2023 | €17.8b | €5.1b | €404.7m | 40x | 44x | 3.5x |
| Sat, 04 Nov 2023 | €16.4b | €5.1b | €408.5m | 35.8x | 40x | 3.2x |
| Mon, 02 Oct 2023 | €18.1b | €5.1b | €408.5m | 39.2x | 44.2x | 3.5x |
| Wed, 30 Aug 2023 | €19.4b | €5.2b | €350.6m | 41.5x | 55.3x | 3.7x |
| Fri, 28 Jul 2023 | €18.9b | €5.5b | €434.8m | 37x | 43.6x | 3.4x |
| Sun, 25 Jun 2023 | €19.5b | €5.5b | €434.8m | 37.9x | 45x | 3.5x |
| Tue, 23 May 2023 | €20.4b | €5.5b | €434.8m | 39.8x | 47x | 3.7x |
| Thu, 20 Apr 2023 | €20.4b | €5.5b | €669.3m | 24.9x | 30.4x | 3.7x |
| Sat, 18 Mar 2023 | €18.7b | €5.5b | €669.3m | 22.9x | 28x | 3.4x |
| Mon, 13 Feb 2023 | €18.9b | €5.9b | €1.1b | 13.7x | 17.2x | 3.2x |
| Wed, 11 Jan 2023 | €18.6b | €5.9b | €1.1b | 13.6x | 16.9x | 3.2x |
| Fri, 09 Dec 2022 | €17.4b | €5.9b | €1.1b | 12.6x | 15.8x | 3x |
| Sun, 06 Nov 2022 | €18.2b | €5.9b | €1.1b | 12.9x | 16.5x | 3.1x |
| Tue, 04 Oct 2022 | €17.3b | €5.9b | €1.1b | 12.4x | 15.7x | 2.9x |
| Thu, 01 Sep 2022 | €17.2b | €5.9b | €1.1b | 12.4x | 15.9x | 2.9x |
| Sat, 30 Jul 2022 | €18.5b | €5.8b | €1.3b | 11.2x | 14.2x | 3.2x |
| Mon, 27 Jun 2022 | €19.7b | €5.8b | €1.2b | 11.8x | 15.8x | 3.4x |
| Wed, 25 May 2022 | €20.0b | €5.8b | €1.2b | 12x | 16.1x | 3.4x |
| Fri, 22 Apr 2022 | €26.5b | €5.8b | €1.3b | 15.7x | 20.9x | 4.6x |
| Sun, 20 Mar 2022 | €25.1b | €5.8b | €1.3b | 14.7x | 19.8x | 4.3x |
| Tue, 15 Feb 2022 | €21.1b | €5.5b | €1.1b | 14x | 19x | 3.8x |
Price to Earnings Ratio
19x
Current Industry PE
- There are only 3 companies in the Belgian Pharmaceuticals industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 34% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Belgian Healthcare industry?
| BE Market | 0.066% | |
| Healthcare | -0.51% | |
| Pharma | 0.47% | |
| Pharma | 0.47% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| UCB UCB | €189.25 | 0.6% +€199.2m | 102.0% | PE149.6x | |
| HYL Hyloris Pharmaceuticals | €5.40 | 0.4% +€560.0k | -58.9% | PS21.8x |